SLNO: the cashflow

MyFinsight

For the quarter ending 2025-09-30, SLNO had $170,165K increase in cash & cash equivalents over the period. $43,453K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	26,013	-48,481
Depreciation and amortization	502	1,006
Accretion of premium/discount on marketable securities	371	1,954
Non-cash lease expense	120	364
Amortization of debt issuance costs	9	17
Accrued clinical trial site costs	-	37
Stock-based compensation expense	9,998	24,377
Change in fair value of contingent consideration	614	4,068
Other non-cash reconciling items	-14	-16
Accounts receivable	882	24,624
Inventory	3,916	2,095
Prepaid expenses, other current assets and other assets	948	339
Accounts payable	1,929	-2,603
Accrued compensation	981	1,491
Operating lease liabilities	-115	-74
Other liabilities	9,543	3,434
Net cash used in operating activities	43,454	-45,360
Purchases of property and equipment	1	14
Purchases of marketable securities	163,172	104,764
Maturities of marketable securities	71,730	119,800
Net cash used in investing activities	-91,443	15,022
Proceeds from the sale of common stock, net of issuance costs	215,721	-
Payment of debt issuance costs	0	62
Proceeds from exercise of common stock warrants	0	5,187
Proceeds from exercise of stock options	2,255	13,993
Payment of deferred financing costs	-	178
Tax withholding payments for net share-settled equity awards	0	33
Net cash provided by financing activities	218,154	18,907
Net increase (decrease) in cash and cash equivalents	170,165	-11,431
Cash and cash equivalents at beginning of period	87,928	-
Cash and cash equivalents at end of period	246,662	-

Unit: Thousand (K) dollars